25th May 2010 - Senexis Limited has identified drug candidates from different and novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer’s disease. Their success secures the drawdown of further tranche of funding from the Wellcome Trust to support pre-clinical development of the most promising candidates from the SEN1500 series.Senexis were awarded £2.9 million by the Wellcome Trust, under the Seeding Drug Discovery initiative in 2008, to support selection studies to identify potential drug candidates for pre-clinical development. Successful completion of these studies now triggers the release of funds, enabling Senexis to initiate that planned development and file two further patents to protect this next generation of potentially disease modifying Alzheimer’s drugs.
Using proprietary drug screening technologies, Senexis have identified novel compounds, which target the soluble assemblies of brain proteins that are a toxic form of amyloid. These potential drugs have been selected for their ability to prevent amyloid from aggregating or “clumping together”. The effect of the compounds is to protect against amyloid toxicity, well before the formation of the tell-tale “plaques” that have been used to classify the disease, since the original discoveries of Alois Alzheimer over a century ago... Senexis' Press Release -
